Home  >  Research  >  Labs  >  Cancer Program  >  LABORATORY FOR CANCER MEDICINE

RESEARCH OVERVIEW

The Laboratory for Cancer Medicine team is driving a program of research that aims to discover new ways of treating cancer. The initial focus was on hormone dependent cancers, such as breast and prostate, but in recent years has expanded to include other cancers which may be associated with a poor prognosis – liver, colon, melanoma and head and neck. Our goal is to discover ways to abrogate the key pathways driving the growth of these tumors, with a view to translating some of these discoveries into new therapies.

From the mechanistic point of view, we have had a long-term interest in RNA biology and human disease, and this has led to discoveries of novel RNA-binding proteins that are involved in regulating hormone action in breast and prostate cancer. One of these, SLIRP, is a repressor of nuclear receptor hormone action that we are exploring in the context of prostate and colon cancer. Several other novel regulators of hormone action have been identified (eg. PACT), which are being investigated using genome-wide approaches in the context of their role as activators of prostate cancer growth.

Our interest in RNA biology was a natural fit for developing significant focus in microRNAs and cancer. microRNAs are short non-coding RNAs that play central roles in regulating normal cell growth. They offer great promise in cancer biology, as they present new avenues for diagnostics and therapeutics. Our studies have resulted in the discovery of several “tumor suppressor microRNAs” that suppress key signalling pathways in poor prognostic tumors, such as head and neck, melanoma and liver cancer. One of these, microRNA-7 or miR-7, acts a potent suppressor of cancer cell proliferation and invasion by targeting the EGF-receptor (EGFR) pathway. In parallel with our work to explore the functional biology of miR-7 in EGFR-driven tumors (head and neck, liver, prostate, glioma) using genome-wide approaches and preclinical models, we have established a spin-out company, miReven, which is focused on developing miR-7 as a potential ‘miR replacement therapy” for these cancers which we hope to move into early phase clinical trials in the forthcoming years. 

Professor Peter Leedman AO

Professor Peter Leedman AO

Cancer Medicine (Institute Director)

Read more

LATEST NEWS

Perkins secures biobanking grants to answer important questions in future research

The McGowan Government recently announced that the Harry Perkins Institute will receive two of the 16 grants totalling more than $1.5 million to support Western Australian biobanks. Congratulations to both Professor Grant Morahan who is Head of the Perkins' Centre for Diabetes Research, and Dr Louise Winteringham who leads the…

Read More

NHMRC funding for DEFINER to identify “the right drug for the right patient” in liver cancer

The Harry Perkins Institute's Oncofetal Ecosystem Laboratory, established early in 2021, has received its first NHMRC Ideas Grant in the most recent grants round. This collaborative project run by the Perkins and Curtin University will investigate a new immunotherapy treatment for the most common type of primary liver cancer, hepatocellular…

Read More

Bioengineers deliver innovation award success

Combining engineering thinking with medical research has proved a winning formula for four Perth start-up companies linked to the Harry Perkins Institute of Medical Research in Nedlands. They were winners in the State government’s WA Innovator of the Year (WAIOTY) awards and recipients of grants from the MTPConnect WA Life…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS